China Pharma Holdings Accounts Payables 2011-2026 | CPHI

Accounts payable — are the obligations of an organization to other legal entities or individuals that arise in cases when the company has acquired goods or services on deferred payment terms, has not paid taxes and fees, has wage arrears to employees, or has received loans and other liabilities. Accounts payable arise when an organization has already received some benefit but has not yet paid for it.

Main types of accounts payable

Type of liability	Example
To suppliers and contractors	Goods received but not yet paid for
Taxes and fees	VAT, income tax, etc., not paid on time
Salaries	Employee wages not paid
To budgets	Insurance contributions to funds not paid
To founders	Founders provided borrowed funds
To banks	Overdue loan payments
Other	Fines, penalties, forfeits, customer prepayments, etc.

Impact on the company's financial performance

Liquidity and solvency
Accounts payable are part of short-term liabilities, so they affect liquidity ratios
Financial stability
The higher the share of borrowed funds (including accounts payable), the lower the company's level of independence
Capital turnover
Moderate accounts payable can positively affect working capital by allowing the company to use “free” financing from suppliers (payment deferrals)
Risks and reputation
Large and especially overdue accounts payable may indicate financial difficulties. This can deter investors, partners, and lenders, and at a critical level of debt and lack of resources to repay it, bankruptcy proceedings may be initiated

Annual Accounts Payables China Pharma Holdings

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
225 K	966 K	667 K	927 K	1.23 M	1.37 M	1.06 M	1.14 M	3.06 M	2.82 M	2.55 M	1.88 M	2.84 M	3.11 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
3.11 M	225 K	1.7 M

Quarterly Accounts Payables China Pharma Holdings

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
589 K	531 K	548 K	225 K	390 K	141 K	-	966 K	831 K	414 K	849 K	667 K	436 K	398 K	927 K	927 K	600 K	687 K	1.11 M	1.23 M	1.23 M	1.23 M	1.23 M	1.37 M	1.37 M	1.37 M	1.37 M	1.06 M	1.06 M	1.06 M	1.06 M	1.14 M	1.14 M	1.14 M	1.14 M	3.06 M	3.06 M	3.06 M	3.06 M	2.44 M	2.82 M	2.82 M	2.82 M	2.55 M	2.55 M	2.55 M	2.55 M	1.88 M	1.88 M	1.88 M	1.88 M	2.84 M	2.84 M	2.84 M	5.85 M	3.11 M	3.12 M	2.77 M	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
5.85 M	141 K	1.66 M

Accounts Payables of other stocks in the Drug manufacturers industry

Issuer	Accounts Payables	Price	% 24h	Market Cap	Country
Alimera Sciences ALIM	8.25 M	-	-	$ 142 M	USA
Adamis Pharmaceuticals Corporation ADMP	7.94 M	-	0.86 %	$ 117 M	USA
Aerie Pharmaceuticals AERI	8.28 M	-	-	$ 754 M	USA
AcelRx Pharmaceuticals ACRX	670 K	-	7.5 %	$ 6.35 M	USA
Canopy Growth Corporation CGC	26.1 M	$ 1.07	4.9 %	$ 115 M	Canada
Agile Therapeutics AGRX	9.57 M	-	10.11 %	$ 58.2 M	USA
Assertio Holdings ASRT	9.01 M	$ 12.34	4.86 %	$ 79 M	USA
DURECT Corporation DRRX	1.78 M	-	-	$ 50.1 M	USA
Avadel Pharmaceuticals plc AVDL	7.33 M	-	-	$ 2.06 B	France
Eagle Pharmaceuticals EGRX	19 M	-	-39.89 %	$ 27.7 M	USA
Evolus EOLS	23.4 M	$ 5.03	-0.2 %	$ 324 M	USA
Catalent CTLT	361 M	-	-	$ 11.5 B	USA
Cumberland Pharmaceuticals CPIX	13.9 M	$ 3.06	-0.16 %	$ 43 M	USA
Jupiter Wellness JUPW	2.22 M	-	-	$ 33.6 M	USA
Athenex ATNX	33.7 M	-	-23.39 %	$ 1.76 M	USA
Endo International plc ENDP	94.7 M	-	-	$ 28.9 M	Irlanda
Harrow Health HROW	35.4 M	$ 35.27	1.03 %	$ 1.3 B	USA
Organogenesis Holdings ORGO	28.9 M	$ 2.54	-1.55 %	$ 334 M	USA
Pacira BioSciences PCRX	19.1 M	$ 21.82	-3.83 %	$ 1.01 B	USA
Emergent BioSolutions EBS	112 M	$ 8.14	-2.28 %	$ 417 M	USA
Veru VERU	3.04 M	$ 2.44	2.74 %	$ 329 M	USA
ProPhase Labs PRPH	5.9 M	-	-	$ 5.07 M	USA
TherapeuticsMD TXMD	27 K	$ 2.26	4.15 %	$ 23.6 M	USA
Lannett Company LCI	29.7 M	-	1.15 %	$ 7.11 M	USA
Radius Health RDUS	17.6 M	-	-	$ 1.42 B	USA
Viatris VTRS	1.77 B	$ 13.91	2.92 %	$ 16.7 B	USA
Perrigo Company plc PRGO	474 M	$ 10.38	6.79 %	$ 1.44 B	USA
Neoleukin Therapeutics NLTX	2.6 M	-	-	$ 193 M	Canada
Sonoma Pharmaceuticals SNOA	953 K	$ 2.44	1.22 %	$ 3.03 M	USA
Relmada Therapeutics RLMD	3.51 M	$ 6.42	3.8 %	$ 193 M	USA
Rockwell Medical RMTI	4.52 M	$ 1.06	10.44 %	$ 24.7 M	USA
PetIQ PETQ	139 M	-	1.64 %	$ 400 M	USA
OptiNose OPTN	3.89 M	-	-	$ 1.08 B	USA
SCYNEXIS SCYX	2.22 M	$ 0.92	2.34 %	$ 45.9 M	USA
Recro Pharma REPH	1.31 M	-	-4.76 %	$ 65.3 M	USA
Solid Biosciences SLDB	4.24 M	$ 7.79	4.08 %	$ 318 M	USA
Tilray TLRY	70.8 M	$ 7.0	1.38 %	$ 4.33 B	Canada
Tricida TCDA	10 M	-	-	$ 3.25 M	USA
cbdMD YCBD	1.54 M	$ 0.76	4.11 %	$ 3.28 M	USA
Zynerba Pharmaceuticals ZYNE	1.94 M	-	-	$ 55.5 M	USA
Zomedica Corp. ZOM	1.72 M	-	-0.21 %	$ 98 M	USA